Form 4: Halozyme Therapeutics SVP, Chief Technical Officer Michael LaBarre Executes Option Exercises and Stock Sales Under 10b5-1 Plan
SEC Form 4 Filing
Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, executed option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan.
Summary
- On August 20 and 21, 2024, Michael J. LaBarre, SVP, Chief Technical Officer of Halozyme Therapeutics, exercised options to purchase 10,000 shares of common stock on each day at a price of $16.65 per share.
- Simultaneously, LaBarre sold 10,000 shares on August 20, 2024, at a weighted average price of $61.055, with prices ranging from $60.65 to $61.51.
- On August 21, 2024, he sold 9,900 shares at a weighted average price of $61.741, with prices ranging from $61.325 to $62.32, and an additional 100 shares at $62.34.
- These transactions were executed under a Rule 10b5-1 trading plan adopted on March 9, 2023.
- Following these transactions, LaBarre directly owns 168,176 shares of common stock and 31,861 options to purchase common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, so they don't necessarily indicate a positive or negative outlook on the company's future. However, large insider sales can sometimes create uncertainty.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, which can reassure investors that the sales were not based on insider information.
Risks
- Executive stock sales, even under a 10b5-1 plan, can sometimes be perceived negatively by investors, potentially creating short-term price pressure.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.
Stakeholder Impact
- Shareholders may react to the news of executive stock sales, potentially impacting the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| February 12, 2019 | Date the options were granted, vesting one-fourth on the first anniversary and then 1/48th monthly thereafter. |
| March 9, 2023 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| August 20, 2024 | Date of option exercise and stock sale. |
| August 21, 2024 | Date of option exercise and stock sale. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.